Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor regimen.

Journal of medical virology - 1 Mar 2011

Lillemark Marie Rathcke, Gerstoft Jan, Obel Niels, Kronborg Gitte, Pedersen Court, Jørgensen Louise Bruun, Madsen Tina Vasehus, Katzenstein Terese Lea

Abstract excerpt

The use of highly active antiretroviral treatment (HAART) regimens with unboosted protease inhibitors (PIs) has resulted in a high level of virological failure primarily due to the development of resistant virus. Current boosted PI regimens combine successfully low-dose ritonavir (r) with a second PI. The aim of the study was to estimate the proportion of patients, in a population based setting, who develop...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Denmark

Share to Genes, gag

Share to Genes, pol

Share to Protease Inhibitors

Share to Ritonavir

Share to Viral Load

Source

Identifiers

PMID: 21264856
DOI: 10.1002/jmv.21997

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor regimen.PMID 21264856Read ↗

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.Semantic proximity Read ↗

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.Semantic proximity Read ↗

Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients.Semantic proximity Read ↗

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.Semantic proximity Read ↗

Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.Semantic proximity Read ↗

Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.Semantic proximity Read ↗

Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.Semantic proximity Read ↗

Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.Semantic proximity Read ↗

Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.Semantic proximity Read ↗

Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Outcomes after virologic failure of first-line ART in South Africa.Semantic proximity Read ↗

Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.